Biomarker & Intervention Discovery
Bladder Cancer
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
Spontaneous remissionNMIBC: 50-70% recurrence within 5 years; MIBC: progression to metastatic in 50% without radical treatment; spontaneous…
Best-intervention remissionNMIBC: BCG intravesical immunotherapy: 70% reduction in recurrence, 30-40% reduction in progression; MIBC with…
Gap sizeLarge — EV + pembrolizumab is a major advance but not yet universally standard; BCG supply shortage is a persistent…
Primary barrieraccess
Full remission profile →
Remission & chronicity
Spontaneous remission
NMIBC: 50-70% recurrence within 5 years; MIBC: progression to metastatic in 50% without radical treatment; spontaneous remission essentially zero
Best-intervention remission
NMIBC: BCG intravesical immunotherapy: 70% reduction in recurrence, 30-40% reduction in progression; MIBC with neoadjuvant cisplatin + radical cystectomy: 5-year survival 50-60% (vs 45% cystectomy alone); metastatic with enfortumab vedotin + pembrolizumab: 31.5 months OS vs 16.1 months cisplatin (EV-302/KEYNOTE-A39)
Gap size
Large — EV + pembrolizumab is a major advance but not yet universally standard; BCG supply shortage is a persistent clinical crisis in NMIBC
BCG shortage (since 2012, persistent) means many NMIBC patients cannot receive standard treatment; gemcitabine + mitomycin as alternative to BCG established as FDA-cleared 2024 (CISTO trial); EV + pembrolizumab is a genuine paradigm change for metastatic disease but requires PD-L1 testing integration
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Bladder Cancer” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."